A ladder, priced at every rung
The product page prices six dose steps, from the starting strength to the maximum, each described as four weekly injections with glycine and B12. Nothing has to be inferred and nothing sits behind the intake.
That is worth something in a category where a starting figure is usually the only number published. It also means the cost of titrating up is visible before the first purchase rather than after the third.
Twenty-three days is not a month
The same product page offers the kit outright or on a subscription at a lower figure, and states in the same line that the subscription renews every twenty-three days.
A four-week supply billed every twenty-three days is billed more often than it is consumed. Over a year that is roughly sixteen charges rather than twelve or thirteen. We have recorded that row as not monthly for exactly this reason; twenty-six of the one hundred and fifty-eight sellers here carry at least one figure that is not a monthly rate.
Nothing on the page explains the interval, and the outright purchase carries no such condition.
Named doctors, no named company
Four physicians are named on the homepage and one is identified as medical director on the product page. Fifty of the one hundred and fifty-eight sellers here name an individual clinician, and this is one of them.
Against that, no legal entity appears anywhere. The homepage and the terms page were read in full and neither carries a company suffix of any kind. A named doctor without a named company tells you who might write the prescription and not who takes your money.
The pages also carry a great deal of customer-review text that quotes other sellers' prices. Those are shoppers talking. None of them is recorded here.
Citizen Meds's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (compounded) | $185per home kit of four weekly injections with glycine and B12, which is four weeks and not a calendar month; the published ladder continues 5 mg $295, 7.5 mg $345, 10 mg $395, 12.5 mg $445 and 15 mg $545 | September 2026source |
| Tirzepatide (compounded) | $316the same kit is $395 outright or $316 on a subscription that the seller's own line says renews "every 23 days" - shorter than a calendar month and shorter than the four-week supply the kit contains | September 2026source |
| Semaglutide (compounded) | $125the homepage prices semaglutide at $125 against a struck $299 and tirzepatide at $145 against a struck $399, while the product pages price the first tirzepatide kit at $185 - the two surfaces do not agree, and no unit is stated beside the homepage figures | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Citizen Meds's current price →Good fit if
- Buyers who want every dose step priced before they start.
- Readers who prefer to buy kits outright rather than enter a subscription.
- People who want a named medical director rather than a category.
Look elsewhere if
- Anyone who needs to know which company they are buying from.
- Buyers who want the billing interval to match the supply.
- Readers who want the compounding pharmacy named.
- Anyone comparing on a headline figure; the homepage and product pages disagree.
How this review was verified
- Read the homepage and two product pages on 6 September 2026, comparing requested to effective paths and running a nonsense path against the host in the same run, which returned a clean not-found status.
- Joined adjacent text nodes before matching prices; the subscription line splits its figures across elements and a per-node reader would have missed the discounted rate entirely.
- Read the terms page in full and searched it for any company suffix; the absence is recorded as a census, not as an impression.
- Separated the seller's own figures from the prices quoted inside customer reviews, and recorded none of the latter.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.